Country: Evrópusambandið
Tungumál: enska
Heimild: EMA (European Medicines Agency)
Inactivated Schmallenberg virus, strain BH80/11-4
Zoetis Belgium SA
QI02AA
Inactivated Schmallenberg virus, strain BH80/11-4
Cattle; Sheep
Immunologicals for bovidae, Inactivated viral vaccines
For active immunisation of cattle and sheep from 3.5 months of age to prevent viraemia associated with infection by Schmallenberg virus.
Revision: 3
Authorised
2015-02-06
15 3B B. PACKAGE LEAFLET 16 PACKAGE LEAFLET: ZULVAC SBV SUSPENSION FOR INJECTION FOR CATTLE AND SHEEP 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT Marketing authorisation holder: Zoetis Belgium SA Rue Laid Burniat 1 1348 Louvain-la-Neuve BELGIUM Manufacturer responsible for batch release: Zoetis Manufacturing & Research Spain, S.L. Ctra. de Camprodón, s/n° Finca La Riba Vall de Bianya Gerona, 17813 SPAIN 2. NAME OF THE VETERINARY MEDICINAL PRODUCT Zulvac SBV suspension for injection for cattle and sheep 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) ACTIVE SUBSTANCE: AMOUNT PER 2 ML DOSE (CATTLE) AMOUNT PER 1 ML DOSE (SHEEP) Inactivated Schmallenberg virus, strain BH80/11-4 RP* ≥ 1 RP* ≥ 1 _ _ ADJUVANTS: Aluminium hydroxide Quil-A ( _Quillaja saponaria_ _ _ saponin extract) 385.2 mg (4 mg Al 3+ ) 0.4 mg 192.6 mg (2 mg Al 3+ ) 0.2 mg EXCIPIENT: Thiomersal 0.2 mg 0.1 mg *Relative potency (mice potency test) compared to a reference vaccine that was shown efficacious in the target animal species. Off-white or pink liquid. 4. INDICATION(S) Cattle: For active immunisation of cattle from 3.5 months of age to reduce viraemia* associated with infection by Schmallenberg virus. Onset of immunity: 2 weeks after completion of the primary vaccination course. 17 Duration of immunity: 1 year after completion of the primary vaccination course. Sheep: For active immunisation of sheep from 3.5 months of age to reduce viraemia* associated with infection by Schmallenberg virus. Onset of immunity: 3 weeks after vaccination. Duration of immunity: 6 months after vaccination. Vaccination of breeding sheep before pregnancy according to the recommended schedule described in section 8 results in reduction of viraemia* and transplacental infection associated with infection by Schmallenberg virus during the first trimester of pregnancy. *Below the level of detection by the validated RT-PCR method at 3.6 log 10 RNA copi Lestu allt skjalið
1 ANNEX I 0B SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Zulvac SBV suspension for injection for cattle and sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE SUBSTANCE: AMOUNT PER 2 ML DOSE (CATTLE) AMOUNT PER 1 ML DOSE (SHEEP) Inactivated Schmallenberg virus, strain BH80/11-4 RP* ≥ 1 RP* ≥ 1 _ _ ADJUVANTS: Aluminium hydroxide Quil-A ( _Quillaja saponaria_ saponin extract) _ _ 385.2 mg (4 mg Al 3+ ) 0.4 mg 192.6 mg (2 mg Al 3+ ) 0.2 mg EXCIPIENT: Thiomersal 0.2 mg 0.1 mg *Relative potency (mice potency test) compared to a reference vaccine that was shown efficacious in the target animal species. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Suspension for injection. Off-white or pink liquid. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle and sheep. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Cattle: For active immunisation of cattle from 3.5 months of age to reduce viraemia* associated with infection by Schmallenberg virus. Onset of immunity: 2 weeks after completion of the primary vaccination course. Duration of immunity: 1 year after completion of the primary vaccination course. Sheep: For active immunisation of sheep from 3.5 months of age to reduce viraemia* associated with infection by Schmallenberg virus. Onset of immunity: 3 weeks after vaccination. Duration of immunity: 6 months after vaccination. Vaccination of breeding sheep before pregnancy according to the recommended schedule described in section 4.9 results in reduction of viraemia* and transplacental infection associated with infection by Schmallenberg virus during the first trimester of pregnancy. 3 *Below the level of detection by the validated RT-PCR method at 3.6 log 10 RNA copies/ml of plasma for cattle and at 3.4 log 10 RNA copies/ml of plasma for sheep. 4.3 CONTRAINDICATIONS None. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Vaccinate healthy animals only. No information is available on the use of the vaccine in seropositive animals including those with Lestu allt skjalið